Issue 4 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

28

No.

4

April 29, 2005Apr 29, 2005

Free

DOWNLOAD THE PDF

NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit

U.S., Canada Begin ExCel Trial To Evaluate Aromasin For Breast Cancer Prevention

Avastin Improves PFS In Advanced Breast Cancer

Preoperative Drug Combo Benefits HER-2 Breast Cancer

Combination Radiation/Vaccine May Benefit Some Patients

“Inoperable” Prostate Cancer May Be Operable, Curable

Benefit Seen In Novel Drug That Treats Gleevec Resistance

NCI’s Rosenberg Confirms 2002 Immunotherapy Results

NCI-Approved Clinical Trials

Recent Issues

Volume 52 | Issue 15 - April 17, 2026

Volume 52 | Issue 14 - April 10, 2026

Volume 52 | Issue 13 - April 03, 2026

Volume 52 | Issue 12 - March 27, 2026

Volume 52 | Issue 11 - March 20, 2026

Volume 52 | Issue 10 - March 13, 2026